Human Mesenchymal Stem Cells (T-MSC™) for treatment of autoimmune disease
ImStem Biotechnology, Inc. (abbreviated ImStem), is a biotech company, incorporated and operating in Connecticut. ImStem is focusing on developing off-shelf cell therapeutic product derived from human pluripotent stem cells for tissue repair, cancer and autoimmune diseases treatment. With $1.13 million support from Connecticut Regenerative Medicine Research Fund, our first product IMS001 targeting multiple sclerosis has passed pre-IND meeting phase with FDA, an IND filing is anticipated for 2017.
Xiaofang Wang, VP/CTO
Michael Men, President/CEO